Evidence map›Paper›PMID 39738784›Full record

ArticleEJNMMI physics2024

Ultra-fast [

Xueqian Yang, Meiqi Wu, Menglin Liang, Haiqiong Zhang, Bo Li, Chenhui Mao, Liling Dong, Yuan Wang, Haiqun Xing, Chao Ren and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05023564 (Peking Union Medical College Hospital), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05023564 recruitingnot on this map

Peking Union Medical College Hospital (PUMCH) Dementia Longitudinal Cohort Study

TypeobservationalSponsorPeking Union Medical College HospitalRan2020 to 2040Enrolled20,000ConditionsDementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia, Mixed
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Impact of reducedEJNMMI physics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xueqian Yang *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Meiqi Wu *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Menglin LiangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Haiqiong ZhangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Bo LiDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Chenhui MaoDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Liling DongDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Yuan WangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Haiqun XingDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Chao RenDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Zhenghai HuangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Qingxiang WenBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
Qi GeCentral Research Institute, United Imaging Healthcare, Shanghai, 201807, China.
Zhengqing YuCentral Research Institute, United Imaging Healthcare, Shanghai, 201807, China.
Feng FengDepartment of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jing GaoDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China. gj107@163.com.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China. huoli@pumch.cn.ORCID http://orcid.org/0000-0003-1216-083X

Funding

CAMS innovation fund for medical science CIFMS-2021-I2M-1-002CAMS innovation fund for medical science CIFMS-2021-I2M-1-025CAMS innovation fund for medical science CIFMS-2022-I2M-C&T-A-003National High Level Hospital Clinical Research Funding 2022-PUMCH-B-070National High Level Hospital Clinical Research Funding 2022-PUMCH-B-071National Key Research and Development Program of China 2016YFC0901500National Key Research and Development Program of China 2020YFA0804500National Key Research and Development Program of China 2020YFA0804501National Natural Science Foundation of China 22022601National Natural Science Foundation of China 82071967
6 · The paper itself

Abstract

backgroundThere is a need for faster amyloid PET scans to reduce patients' discomfort, minimize movement artifacts, and increase throughput. The recently introduced uMI Panorama PET/CT system featuring enhanced spatial resolution and sub-200ps TOF offers the potential for shorter scan duration without sacrificing image quality or efficacy to detect Aβ deposition. The study aims to establish a faster acquisition protocol for [

methodsThirty-eight participants (29 Aβ positive and 9 Aβ negative) from a prospective dementia cohort at Peking Union Medical University Hospital underwent routine [

resultsThe subjective image quality evaluation and Aβ detectability results from the two physicians showed both good intra-reader and inter-reader agreements (Cohen's kappa coefficient: 0.759-1.000). The subjective and objective image qualities of the G2min scans were comparable to the G10min scans, whereas adequate image quality was achieved with the G1min and G45s scans (5-point score ≥ 3). Subjective visual diagnosis by two physicians yielded consistent accuracy for G10min, G2min, and G1min groups, but lower specificity for G45s and G30s groups. The objective detection of Aβ status by cortex SUVr across all scan durations maintained perfect discriminatory efficiency and relatively high effect size (Hedge's G: 2.48-2.54).

conclusionsA 1-min ultra-fast scan is feasible for [ CLINICAL

trial registrationNCT05023564. Registered September 2022 https://clinicaltrials.gov/search?term=NCT05023564 .

Indexed as

[18F]florbetapirDigital PET/CTImage qualityUltra-fast PET scanβ-Amyloid

Identifiers

PMID39738784
PMCPMC11683033

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.